Complete Genomics, Inc., a leader in whole human genome sequencing, announced today that leading UK charity Epilepsy Society has become the third customer of the company's newly introduced Revolocity system, a supersequencer for large-scale, high-quality whole genome and whole exome sequencing.
"Genome sequencing holds the promise of improving our understanding of epilepsy," explained Epilepsy Society CEO Angela Geer. "The Revolocity™ system represents a major breakthrough in terms of the quality and quantity of whole genome sequencing information needed to drive clinical research into potential new treatments." The Epilepsy Society will install the system at its Chalfont Centre site.
"As the UK's leading funder and provider of epilepsy research and services, Epilepsy Society is uniquely positioned to advance the use of sequencing technology to improve the lives of people with epilepsy," said Complete Genomics CEO Clifford A. Reid, PhD. "We are proud to support their efforts in this often debilitating disease that affects as many as 50 million people worldwide."
Complete Genomics has been at the forefront of advances in DNA sequencing and computational technologies, sequencing more than 20,000 whole human genomes and driving the adoption of next generation sequencing in clinical research. The company's Revolocity™ system is the only total solution for sample-to-variant sequencing and includes all components necessary to perform DNA extraction, library preparation, sequencing, data analysis, and reporting. System operations are seamlessly integrated through the Revolocity™ workflow management system.
Complete Genomics, Inc., will conduct a luncheon workshop on October 7, Advances in Genome Sequencing, at the 65th Annual Meeting of the American Society of Human Genetics (ASHG)in Baltimore, Maryland.